Johnston, Stephen
O’Shaughnessy, Joyce
Martin, Miguel
Huober, Jens
Toi, Masakazu http://orcid.org/0000-0003-1488-9958
Sohn, Joohyuk
André, Valérie A. M.
Martin, Holly R.
Hardebeck, Molly C.
Goetz, Matthew P. http://orcid.org/0000-0002-4383-270X
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 22 September 2020
Accepted: 27 May 2021
First Online: 22 June 2021
Competing interests
: S.J. reports consulting/advisory fees and research funding from AstraZeneca, Eli Lilly and Company, Novartis, Pfizer, and Puma Biotechnology; research funding from Roche/Genentech; and is on the Speaker’s bureau of AstraZeneca, Novartis, Pfizer, Eisai, and Roche/Genentech. J.O.’S. reports consulting fees and is on the advisory boards of AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Eli Lilly and Company, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, prIME Oncology, Roche, Seattle Genetics, Syndax, Pharmaceuticals, and Takeda. M.M. reports grants and personal fees from Roche, Novartis, and, Puma Biotechnology; personal fees from Pierre Fabre, AstraZeneca, Taiho Oncology, Daiichi Sankyo, Pfizer, and Eli Lilly and Company. J.H. reports personal fees from Eli Lilly and Company, Novartis, Pfizer, AstraZeneca, Roche, MSD, Celgene, Eisai, AbbVie Inc., and Hexal; grants from Novartis, and Hexal; travel funding from Pfizer, Roche, Celgene, and Daiichi Sankyo. M.T. reports research grants from Chugai, Takeda, Pfizer, Kyowa-Hakko-Kirin, Taiho Oncology, JBCRG Association, Eisai, AstraZeneca, Daiichi Sankyo, Astellas, Shimadzu, AFI Technologies, and Nippon Kayaku; honoraria from Chugai, Takeda, Pfizer, Kyowa-Hakko-Kirin, Taiho Oncology, Eisai, Daiichi Sankyo, AstraZeneca, Eli Lilly and Company, MSD, Genomic Health, Novartis, Konica Minolta, BMS, Shimadzu, Yakult, and Nippon Kayaku; advisory role in Kyowa-Hakko-Kirin, Daiichi Sankyo, Athenex Oncology, and Bertis; and is on the board of directors of Japan Breast Cancer Research Group Association, Organization for Oncology and Translational Research, and Kyoto Breast Cancer Research Network. J.S. reports research grant and funding from MSD, Roche, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer, Bayer, GSK, CONTESSA, and Daiichi Sankyo. V.A.M.A., H.R.M. and M.C.H. are employees of Eli Lilly and Company and hold company stocks. M.P.G. reports consulting fees to his organization from Eagle Pharmaceuticals, Eli Lilly and Company, Biovica, Novartis, Sermonix Pharmaceuticals, Context Therapeutics, Pfizer, and Biotheranostics; grants from Pfizer, Eli Lilly and Company, and Sermonix Pharmaceuticals.